Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer
Incyte announced that the European Commission has approved its drug Zynyz for an additional rare cancer, specifically for adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal. This marks the drug’s second approval in Europe, as it was previously approved for Merkel cell carcinoma. The approval allows Zynyz to be used in combination with carboplatin and paclitaxel for this condition.